Moscontin Lp (Morphine Sulfate)

Morphine sulfate, the active ingredient in Moscontin Lp, is an opioid analgesic presented as an unknown strength extended‑release oral tablet for oral use. It treats moderate to severe acute pain and chronic pain management in adults.

GNH USA supplies Moscontin Lp as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Morphine sulfate is an opioid analgesic used in the management of pain.

- Moderate to severe acute pain: provides rapid analgesia for postoperative or trauma‑related pain. - Chronic cancer pain: maintains continuous pain control for patients with malignant disease. - Chronic non‑cancer pain: offers long‑term relief for conditions such as severe osteoarthritis when other therapies are insufficient.

Morphine sulfate may cause a range of adverse reactions, varying from mild to potentially life‑threatening.

Common Side Effects: - Nausea - Constipation - Drowsiness - Dizziness - Dry mouth - Sweating

Serious or Rare Side Effects: - Respiratory depression - Severe hypotension - Adrenal insufficiency - Opioid dependence or misuse - Allergic reactions (e.g., rash, anaphylaxis) - QT interval prolongation

When prescribing Moscontin Lp, clinicians should observe several safety precautions to minimize risk. - Assess pain severity and prior opioid exposure: determine appropriate starting dose. - Initiate therapy at the lowest effective dose: titrate cautiously. - Avoid use in patients with untreated respiratory depression: monitor breathing. - Monitor for signs of addiction, tolerance, or misuse: conduct regular assessments. - Use with caution in renal or hepatic impairment: adjust dosing as needed. - Pregnancy Category C: weigh maternal benefit against fetal risk. - Store at ambient temperature: keep in the original pack, protect from moisture and heat.

Morphine sulfate can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Concomitant CNS depressants (e.g., benzodiazepines, barbiturates): risk of profound sedation and respiratory depression. - Monoamine oxidase inhibitors (MAOIs): may precipitate severe hypertension or serotonin syndrome. - Other opioids or opioid agonists: additive respiratory depression and sedation.

Moderate Interactions (Monitor Closely): - Anticholinergic agents: may increase constipation severity. - Diuretics: can enhance hypotensive effects of morphine. - Selective serotonin reuptake inhibitors (SSRIs): may raise risk of serotonin syndrome.